VERA
Income statement / Annual
Last year (2024), Vera Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Vera Therapeutics, Inc.'s net income was -$152.15 M.
See Vera Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$1.86 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
-$846,000.00
|
$176,000.00
|
$251,000.00
|
$509,000.00
|
| Gross Profit |
$0.00
|
$1.86 M
|
$846,000.00
|
-$176,000.00
|
-$251,000.00
|
-$509,000.00
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$126.17 M
|
$78.23 M
|
$68.99 M
|
$22.48 M
|
$45.21 M
|
$7.29 M
|
| General & Administrative Expenses |
$41.00 M
|
$23.79 M
|
$21.91 M
|
$11.92 M
|
$4.04 M
|
$4.41 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$41.00 M
|
$23.79 M
|
$21.91 M
|
$11.92 M
|
$4.04 M
|
$4.41 M
|
| Other Expenses |
$0.00
|
$0.00
|
$1.85 M
|
$1.79 M
|
-$1.08 M
|
$0.00
|
| Operating Expenses |
$167.17 M
|
$102.01 M
|
$90.90 M
|
$34.40 M
|
$49.25 M
|
$11.70 M
|
| Cost And Expenses |
$0.00
|
$102.01 M
|
$90.90 M
|
$34.40 M
|
$49.25 M
|
$11.70 M
|
| Interest Income |
$20.71 M
|
$4.19 M
|
$1.75 M
|
$15,000.00
|
$8,000.00
|
$159,000.00
|
| Interest Expense |
-$7.63 M
|
$0.00
|
$992,000.00
|
$20,000.00
|
$166,000.00
|
$51,000.00
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
-$846,000.00
|
$176,000.00
|
$251,000.00
|
$509,000.00
|
| EBITDA |
-$167.17 M |
-$102.01 M |
-$90.90 M |
-$34.23 M |
-$53.00 M |
-$11.19 M |
| EBITDA Ratio |
0
|
-54.79
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-54.79
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$15.02 M
|
$6.02 M
|
$1.85 M
|
$1.79 M
|
-$1.17 M
|
$108,000.00
|
| Income Before Tax |
-$152.15 M
|
-$95.99 M
|
-$89.06 M
|
-$32.61 M
|
-$53.41 M
|
-$11.85 M
|
| Income Before Tax Ratio |
0
|
-51.55
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
-$1,000.00
|
$1,000.00
|
$1,000.00
|
$1,000.00
|
$1,000.00
|
$1,000.00
|
| Net Income |
-$152.15 M
|
-$95.99 M
|
-$89.06 M
|
-$32.61 M
|
-$53.41 M
|
-$11.85 M
|
| Net Income Ratio |
0
|
-51.55
|
0
|
0
|
0
|
0
|
| EPS |
-2.75 |
-2.25 |
-3.35 |
-1.53 |
-14.4 |
-3.46 |
| EPS Diluted |
-2.75 |
-2.25 |
-3.35 |
-1.53 |
-14.4 |
-3.46 |
| Weighted Average Shares Out |
$55.33 M
|
$42.71 M
|
$26.57 M
|
$21.28 M
|
$3.71 M
|
$3.42 M
|
| Weighted Average Shares Out Diluted |
$55.33 M
|
$42.71 M
|
$26.57 M
|
$21.28 M
|
$3.71 M
|
$3.42 M
|
| Link |
|
|
|
|
|
|
